Idarucizumab for Dabigatran Reversal – Full Cohort Analysis
11 Jul, 2017 | 17:19h | UTCIdarucizumab for Dabigatran Reversal – Full Cohort Analysis – New England Journal of Medicine (free)
Commentary: Safety and Efficacy of Dabigatran Reversal Agent Confirmed – Physician’s First Watch (free)